Hill-Rom Holdings (NYSE:HRC) said it will lay off about 3% of its workforce, or roughly 200 workers, as it maneuvers to confront the medical device tax set to go into effect next year.
Smith & Nephew
Federal Circuit reverses course, reinstates Marine Polymer’s $29M win over Hemcon | Legal News
A sharply split federal appeals court reversed course and reinstated a $29.4 million win for Marine Polymer Technologies in its wound dressing patent spat with HemCon Medical Technologies.
The U.S. Court of Appeals for the Federal Circuit, in an en banc decision joined in full by 5 of 9 judges on the panel, ruled that the "intervening rights" of a company accused of patent infringement are only valid when patent claim language is changed during re-examination.
MassDevice.com +3 | The top 3 med-tech stories for March 13, 2012.
Say hello to MassDevice +3, a bite-sized view of the top three med-tech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else today, make sure you’re still in the know with MassDevice +3.
Metal hip developer deposed in ongoing DePuy lawsuit | Legal News
Hip Study: Smith & Nephew touts study results for new metal-on-metal implants
British orthopedic titan Smith & Nephew (NYSE:SNN) touted the results of a 10-year study of its metal-on-metal hip resurfacing implants, hoping to differentiate its implants from the high-profile recall of rival DePuy’s ASR device.
VCs press Senate on “IPO On Ramp” bill | Wall Street Beat
The National Venture Capital Assn. is spearheading a drive to get a bill through the U.S. Senate that would make it easier for small companies to raise money by going public.
The "IPO On Ramp" measure would ease the regulatory requirements for IPOs and temporarily reduce the reporting burdens imposed by the Sarbanes-Oxley Act.
Report: Hundreds of thousands exposed to toxic compounds from metal-on-metal hip implants
Hundreds of thousands of patients may have been exposed to toxic compounds from metal-on-metal implants, according to an investigation by the British Medical Journal and BBC Newsnight, putting them at risk of developing cancer, cardiomyopathy, muscle and bone destruction and changes to their DNA.
Recent FCPA prosecutions an ominous trend for med-tech? | Legal News
Medical device makers with overseas operations may have to tread more carefully in light of a recent Justice Dept. decision to ding British orthopedic titan Smith & Nephew (NYSE:SNN) for $22 million to settle bribery charges.
Beyond the stiff penalty, the decision may also represent a shift in the way the SEC and DOJ view government entities in foreign countries, according to the American Health Lawyers Assn.
Ortho market growth stable but low | Wall Street Beat
The market for hip and knee implants is stable but mired in a low-growth stage, according to analysts who attended the American Academy of Orthopedic Surgeons conference in San Francisco last week.
Although the abrupt departure of Stryker CEO Steve MacMillan drew the lion’s share of attention at the AAOS event, analysts from Barclays Capital and Leerink Swann agreed that the sector’s outlook calls for low-single-digit growth.
MassDevice.com +7 | The top 7 med-tech stories for the week of February 6, 2012.
Say hello to MassDevice +7, a bite-sized view of the top seven med-tech stories of the week. This latest feature of MassDevice.com’s coverage highlights our seven biggest and most influential stories from the week’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
If you read nothing else this weekend, make sure you’re still in the know with MassDevice +7.
Smith & Nephew pays $22M fine for 10 years of bribery in Greece
British orthopedic titan Smith & Nephew (NYSE:SNN) must pay $22.2 million to settle charges of bribing Greek doctors for more than a decade, according to SEC documents.
The complaint alleges that Smith & Nephew subsidiaries used a distributor that created a "slush fund" to bribe doctors working at government hospitals in Greece.